Elekta AB stock (SE0000163628): Citigroup adjusts target price as focus stays on radiation therapy growth

Citigroup has raised its target price for Elekta AB but kept a sell rating, drawing new attention to the Swedish radiation therapy specialist and its positioning in the global oncology equipment market.

Citigroup recently updated its view on Elekta AB, lifting the target price for the Swedish radiation therapy specialist to 45 Swedish kronor while maintaining a sell rating on the stock, according to a report summarized by Börsennews on May 21, 2026 (Zonebourse as of 05/21/2026). The cautious stance highlights ongoing debate among investors about growth prospects and profitability in Elekta’s core radiotherapy and oncology solutions business.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Elekta
• Sector/industry: Medical technology / radiation oncology
• Headquarters/country: Stockholm, Sweden
• Core markets: Hospitals and cancer centers in Europe, North America, Asia-Pacific, Latin America
• Key revenue drivers: Linear accelerators, stereotactic radiosurgery systems, software for treatment planning and oncology information management, service contracts
• Home exchange/listing venue: Nasdaq Stockholm (ticker: EKTA B)
• Trading currency: Swedish krona (SEK)

Elekta AB: core business model

Elekta AB focuses on precision radiation medicine, providing hardware and software that enable oncologists and neurosurgeons to treat tumors with high accuracy while trying to minimize damage to healthy tissue. The company’s systems are installed primarily at hospitals and specialized cancer centers, often forming the backbone of radiotherapy departments. This creates a business model combining one-off equipment sales with recurring service, maintenance and software revenue.

In radiotherapy, customers typically invest in linear accelerators and related systems with long lifespans, often more than a decade, which makes purchase decisions highly strategic. Elekta’s offering aims to integrate imaging, planning and delivery of radiation, and is frequently embedded into broader oncology workflows at major care providers. Because switching vendors can be complex and expensive, established installed bases tend to lead to long-term relationships, often including multi-year service contracts and software upgrades.

The company also addresses radiosurgery, where very precise, high-dose radiation is used for specific brain and body targets. With solutions that are designed for stereotactic treatments, Elekta competes for procedures that may otherwise require surgery. This supports premium pricing for advanced systems in markets that prioritize cutting-edge cancer care. The strategy is to leverage clinical performance, reliability and workflow integration to maintain and expand market share.

Part of Elekta’s business model is based on partnerships with hospitals, universities and research institutions that help validate new treatment techniques and support clinical evidence. These collaborations can contribute to adoption of new technologies while strengthening the company’s reputation with medical professionals. In addition, education and training help clinicians use complex systems effectively, which may further tie customers to Elekta’s ecosystem once they are familiar with its interfaces and protocols.

Main revenue and product drivers for Elekta AB

The largest revenue contributors for Elekta typically come from sales of radiation therapy systems, including linear accelerators used for external beam radiotherapy. These machines often represent high-ticket capital expenditures for hospitals, with follow-on revenue from installation, commissioning and ongoing support. Elekta also sells specialist radiosurgery solutions designed for high-precision treatments in neurosurgery and oncology, allowing healthcare providers to expand their treatment portfolios.

Another important driver is software, which includes treatment planning systems and oncology information systems that manage patient data, imaging and workflow. These software solutions are often sold with licenses and maintenance agreements, resulting in recurring revenue streams that can smooth out the cyclicality of big hardware orders. As hospitals increasingly focus on digitalization and efficiency, integrated software can become an important differentiator.

Service and maintenance contracts are central to Elekta’s financial profile. Radiotherapy equipment must comply with strict safety and performance requirements, and downtime can disrupt patient care. This tends to support demand for OEM service, upgrades and spare parts. Multi-year contracts can provide predictable cash flows and help Elekta deepen relationships with clinical teams, who may rely on the company’s engineers and application specialists for ongoing support.

Beyond traditional radiotherapy, Elekta aims to position itself in the broader precision medicine and image-guided treatment market. This includes technologies that combine advanced imaging with adaptive treatment planning, allowing clinicians to adjust treatments based on changes in tumor position or patient anatomy. Such innovations can justify premium pricing and potentially open new indications, although they may require continued investment in research, development and regulatory processes.

Industry trends and competitive position

The radiation therapy equipment market is shaped by rising global cancer incidence and increasing access to advanced treatments in emerging markets. Elekta competes primarily with large medtech groups offering radiotherapy and imaging solutions, particularly in North America, Europe and parts of Asia. Competition centers on technology performance, clinical evidence, total cost of ownership and service quality, making innovation and reliability key success factors.

Healthcare systems in the United States remain a major driver of global demand for sophisticated oncology equipment, due to high treatment volumes and reimbursement structures that support advanced therapies. For Elekta, a strong presence in the US market is strategically important, as hospitals often look for state-of-the-art radiotherapy solutions and may act as reference customers for other regions. At the same time, procurement processes and regulatory requirements in the US can be demanding, requiring robust clinical and economic data.

Broader industry trends include growing interest in hypofractionation, where patients receive fewer but higher-dose radiation sessions, as well as integration of artificial intelligence into treatment planning and workflow optimization. Vendors that can support clinicians in designing efficient, personalized plans and managing complex patient flows may gain an advantage. Elekta’s focus on software and digital workflows is aligned with these trends, but success depends on continuous R&D investment and effective commercialization.

Why Elekta AB matters for US investors

For US investors, Elekta represents exposure to the global oncology equipment and precision radiation therapy market, which is closely linked to long-term healthcare spending and demographic trends. The company’s systems are installed at US hospitals and cancer centers, which makes its performance partly dependent on American reimbursement frameworks and capital investment cycles. As a non-US issuer, Elekta also adds geographic diversification relative to domestically focused medtech holdings.

US-based investors can follow Elekta through its primary listing on Nasdaq Stockholm as well as through unsponsored ADRs quoted in the United States, which may help some market participants access the shares within local trading hours. Currency movements between the Swedish krona and the US dollar can influence returns for dollar-based portfolios, adding an additional layer of risk and potential opportunity. Regulatory developments affecting medical devices and radiation therapy in the US are likewise relevant for assessing the company’s environment.

Given the importance of oncology in the broader healthcare sector, Elekta’s success or setbacks in launching new technologies, winning tenders or navigating supply chain conditions can offer insights into the health of the radiotherapy segment overall. For investors following the medtech universe, the stock can serve as a case study on how specialized equipment providers balance innovation with profitability and manage competition from larger, more diversified players.

Conclusion

Elekta AB attracts renewed attention after Citigroup raised its target price but kept a sell rating, underscoring mixed sentiment around the stock’s risk-reward profile. The company is firmly positioned in radiation therapy and radiosurgery, markets influenced by long-term cancer trends and capital expenditure cycles at hospitals worldwide. Its business model blends large equipment sales with recurring software and service revenue, while competition and regulatory demands require ongoing innovation. For US investors, Elekta provides specialized exposure to global oncology equipment and European medtech, with additional considerations such as currency effects and access via international trading venues. Whether the updated target from Citigroup signals opportunity or caution ultimately depends on individual risk tolerance, portfolio context and expectations regarding the pace of growth and profitability in precision radiation medicine.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.